stoxline Quote Chart Rank Option Currency Glossary
Intellia Therapeutics, Inc. (NTLA)
22.72  -2.12 (-8.53%)    05-28 16:00
Open: 25.07
High: 25.25
Volume: 1,980,101
Pre. Close: 24.84
Low: 22.635
Market Cap: 2,192(M)
Technical analysis
2024-05-28 4:54:48 PM
Short term     
Mid term     
Targets 6-month :  28.25 1-year :  31.72
Resists First :  24.18 Second :  27.16
Pivot price 25.06
Supports First :  19.37 Second :  16.11
MAs MA(5) :  24.82 MA(20) :  24.52
MA(100) :  26.13 MA(250) :  31.44
MACD MACD :  0.2 Signal :  0.3
%K %D K(14,3) :  32.4 D(3) :  51.8
RSI RSI(14): 38.9
52-week High :  47.47 Low :  19.37
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NTLA ] has closed below the lower bollinger band by 3.5%. Bollinger Bands are 24.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.28 - 25.48 25.48 - 25.62
Low: 22.24 - 22.45 22.45 - 22.59
Close: 22.45 - 22.77 22.77 - 22.99
Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 28 May 2024
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6% - MarketBeat

Sun, 26 May 2024
10416 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Bought by Quest Partners LLC - Defense World

Sun, 26 May 2024
Charles Schwab Investment Management Inc. Boosts Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World

Tue, 14 May 2024
Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts - Simply Wall St

Tue, 14 May 2024
Intellia Earnings: Novel Gene Editing Pipeline Advances; Shares Attractive for Long-Term Investors - Morningstar

Fri, 10 May 2024
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 96 (M)
Held by Insiders 9.496e+007 (%)
Held by Institutions 1.2 (%)
Shares Short 13,500 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.0632e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 7 %
Return on Assets (ttm) 297.4 %
Return on Equity (ttm) -22.9 %
Qtrly Rev. Growth 3.627e+007 %
Gross Profit (p.s.) 0
Sales Per Share -22.76
EBITDA (p.s.) 0
Qtrly Earnings Growth -5.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -394 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -1
Price to Cash Flow 3.72
Stock Dividends
Dividend 0
Forward Dividend 1.459e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android